首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies.
【24h】

A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies.

机译:一种简单的等度HPLC测定法,用于确定不同生物基质中利奈唑胺的浓度,用于体内和体外研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Linezolid is an important therapeutic option for the treatment of infections caused by multiresistant Gram-positive bacteria such as vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). However, the clinical benefit of linezolid is threatened by the emergence of resistant strains of MRSA and VRE reported in North America and Europe. For effective antimicrobial treatment, it is extremely important to have exact knowledge of drug concentrations at the site of action. METHODS: A simple HPLC method for the rapid and precise determination of linezolid in different biomatrices (e.g., plasma, soft tissue, bone, dialysis fluid and used microbiological broth) was developed and validated. Proteins were precipitated with acetonitrile and separation was performed on a reversed-phase C8 column with a mobile phase consisting of water/acetonitrile (80:20, v/v). UV detection was performed at 251 nm. RESULTS: This method has a lower limit of quantification of 0.3 microg/mL and a linear calibration range of 0.5-40 microg/mL. The method showed excellent reproducibility, with an inter- and intra-day assay precision of <5% (% relative standard deviation), as well as excellent accuracy, with inter- and intra-day assay accuracy ranging from 100.6% to 103.2%. Stability up to 6 months in water and plasma was proven. Quantitative recovery was possible after up to three freeze thaw cycles. CONCLUSIONS: The method is useful in the acquisition of in vivo and in vitro data. It is simple, flexible, specific, precise and reproducible, as well as of adequate sensitivity for clinical use.
机译:背景:利奈唑胺是治疗由多重耐药的革兰氏阳性细菌(如耐万古霉素的肠球菌(VRE)和耐甲氧西林的金黄色葡萄球菌(MRSA))引起的感染的重要治疗选择。但是,利奈唑胺的临床益处受到北美和欧洲报道的MRSA和VRE抗药性菌株的威胁。对于有效的抗菌治疗,至关重要的是确切了解作用部位的药物浓度。方法:开发并验证了一种简单的HPLC方法,可以快速,准确地测定不同生物基质(例如血浆,软组织,骨骼,透析液和使用过的微生物肉汤)中的利奈唑胺。蛋白质用乙腈沉淀,并在反相C8柱上进行分离,流动相由水/乙腈(80:20,v / v)组成。在251nm处进行UV检测。结果:该方法的定量下限为0.3微克/毫升,线性校准范围为0.5-40微克/毫升。该方法显示出优异的重现性,日间和日间测定精度<5%(相对标准偏差%),以及极好的准确性,日间和日间测定精度范围为100.6%至103.2%。在水和血浆中的稳定性长达6个月。经过多达三个冻融循环后,才有可能实现定量恢复。结论:该方法可用于体内和体外数据的采集。它简单,灵活,特异,精确,可重现,并具有足够的临床敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号